Disease · MONDO_0005627
Comparisons in its trials54
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 54
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pemetrexed/Cisplatin vs Placebo/Cisplatin: serious adverse events | 185 of 392 | 132 of 385 | 777 | NCT00415194 | Trial comparisons |
| IMRT vs IMRT Plus Cetuximab: deaths from any cause | 97 of 287 | 87 of 290 | 577 | NCT00956007 | Trial comparisons |
| IMRT vs IMRT Plus Cetuximab: serious adverse events | 50 of 282 | 83 of 276 | 558 | NCT00956007 | Trial comparisons |
| Induction Plus Chemoradiotherapy vs Chemoradiotherapy: deaths from any cause | 39 of 138 | 42 of 135 | 273 | NCT00117572 | Trial comparisons |
| Induction Plus Chemoradiotherapy vs Chemoradiotherapy: serious adverse events | 65 of 138 | 38 of 135 | 273 | NCT00117572 | Trial comparisons |
| IMRT + Cisplatin + Placebo vs IMRT + Cisplatin + Lapatinib: deaths from any cause | 23 of 64 | 26 of 63 | 127 | NCT01711658 | Trial comparisons |
| IMRT + Cisplatin + Placebo vs IMRT + Cisplatin + Lapatinib: serious adverse events | 26 of 59 | 31 of 60 | 119 | NCT01711658 | Trial comparisons |
| Panitumumab Plus Chemotherapy vs Chemotherapy Alone: serious adverse events | 34 of 56 | 27 of 55 | 111 | NCT00454779 | Trial comparisons |
| A: Cetuximab+FHX vs B: Cetuximab + PX: Objective Response Rate to CRT | 3 of 57 | 4 of 53 | 110 | NCT00468169 | Trial comparisons |
| A: Cetuximab+FHX vs B: Cetuximab + PX: deaths from any cause | 14 of 57 | 9 of 53 | 110 | NCT00468169 | Trial comparisons |
| A: Cetuximab+FHX vs B: Cetuximab + PX: Residual Lymph Node Disease | 2 of 57 | 6 of 53 | 110 | NCT00468169 | Trial comparisons |
| A: Cetuximab+FHX vs B: Cetuximab + PX: serious adverse events | 7 of 57 | 14 of 53 | 110 | NCT00468169 | Trial comparisons |
| Boost Arm vs Control Arm: deaths from any cause | 15 of 41 | 14 of 59 | 100 | NCT02031250 | Trial comparisons |
| Boost Arm vs Control Arm: serious adverse events | 12 of 41 | 15 of 59 | 100 | NCT02031250 | Trial comparisons |
| Boost Arm vs Control Arm: Local-regional Control Rate | 7 of 40 | 15 of 41 | 81 | NCT02031250 | Trial comparisons |
| Boost Arm vs Control Arm: Proportion of Patients in Which Hypoperfused/Low-diffusion Subvolumes Overlap With Recurrence Volumes | 12 of 40 | 12 of 41 | 81 | NCT02031250 | Trial comparisons |
| Arm A (Cetuximab and Temsirolimus) vs Arm B (Temsirolimus): serious adverse events | 14 of 40 | 19 of 40 | 80 | NCT01256385 | Trial comparisons |
| Cisplatin + Radiation + Pembrolizumab - Concurrent vs Cisplatin + Radiation + Pembrolizumab - Sequential: Acute Toxicity / DLT Rate | 3 of 41 | 0 of 39 | 80 | NCT02777385 | Trial comparisons |
| Cisplatin + Radiation + Pembrolizumab - Concurrent vs Cisplatin + Radiation + Pembrolizumab - Sequential: deaths from any cause | 11 of 41 | 6 of 39 | 80 | NCT02777385 | Trial comparisons |
| Cisplatin + Radiation + Pembrolizumab - Concurrent vs Cisplatin + Radiation + Pembrolizumab - Sequential: serious adverse events | 21 of 41 | 10 of 39 | 80 | NCT02777385 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005627/comparisons